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Developers of cancer immunotherapy have struggled for
decades to achieve clinical success in using the patient’s
immune system to treat cancer. In the absence of a defined
development paradigm for immunotherapies, conventional
criteria established for chemotherapy were applied to these
agents. This article summarizes the recent lessons for deve-
lopment of agents in the immunotherapy space, describes the
systematic creation of a new clinical development paradigm
for cancer immunotherapies and integrates this paradigm
with the emerging methodological framework for a new
clinical sub-specialty of immuno-oncology, which was driven
by the collaborative work between the Cancer Immuno-
therapy Consortium (CIC) of the Cancer Research Institute in
the US and the Association for Cancer Immunotherapy (CIMT)
in Europe. This new framework provides a better defined
development path and a foundation for more reproducible
success of future therapies.
Background
Immunotherapy of cancer has a history full of important
discoveries that goes back to the late nineteenth century, when
William B. Coley observed tumor regressions following the
injection of a bacterial broth also known as Coley’s toxins into
malignant lesions. This was followed by a series of discoveries but
also draw-backs that have led to marked fluctuations in attitude
toward cancer immunotherapy.
1,2 Until recently, this field has not
systematically assessed and integrated the available knowledge on
the unique aspects of immune therapeutic approaches to establish
a methodological framework for rational clinical development that
enables reproducible clinical success.
3,4 Such reproducible success
is needed for the cancer immunotherapy field to improve the
perception among stakeholders and rise as a recognized sub-
specialty within oncology and human medicine.
Cancer immunotherapies, ranging from monoclonal antibodies
to complex cellular vaccines, have long been considered as
promising, and are expected to provide clinical benefit with
focused or minimal toxicities. The fact that they have not yet
delivered on that promise may be due to the incomplete scientific
understanding of tumor immunology on one hand and the use of
conventional development plans as defined for the distinctly
different but more familiar chemotherapeutic agents on the other
hand. Thus, some immunotherapy failures can probably be
explained by their lack of efficacy, while others may be due to an
inadequate approach to their development. Recently, Goldman
and DeFrancesco pointed out that some reasons for develop-
mental failures include “companies not doing their homework”
and asked “what lessons from the list of failures will inform future
practitioners in the field?”
3
Such lessons are now available after having been systematically
defined over the past decade with the aim to improve the
developmental path and enable success in the cancer immuno-
therapy space.
4-6 Driven by the struggle of biotechnology
companies and academic institutions devoted to immunothera-
pies, the Cancer Immunotherapy Consortium [CIC; formerly
Cancer Vaccine Consortium, a program of the non-profit
Cancer Research Institute (CRI)], which was founded for the
advancement of the cancer immunotherapy field, began to create
a systematic framework that would provide the knowledge and
tools needed for their successful development. CIC formed a
partnership with the Association for Cancer Immunotherapy
(CIMT) in Europe, and, with broad contributions from the
scientific and drug development communities developed the
new framework that encompasses the following: a development
paradigm for cancer immunotherapies, harmonized use of
methods for measuring immune response as a foundation for
immune biomarker development,
7,8 improved study designs
5 and
clinical endpoints,
9,10 a publication framework for immune
monitoring results from clinical trials,
11,12 and scientific exchange
and regulatory interactions to inform guidance document
development by regulatory authorities.
13,14
In the last three years the field - for the first time—saw the
clinical proof of success for cancer immunotherapies achieved in
controlled randomized Phase III trials meeting primary survival
endpoints: the first regulatory approvals of a therapeutic cancer
vaccine, sipuleucel-T (Provenge
1) for hormone-refractory pro-
state cancer,
15 and for the T-cell potentiating monoclonal
antibody anti-CTLA-4 (ipilimumab; Yervoy).
16,17 With these
historic milestones reached in two unrelated tumor entities and
two distinct agents, immunotherapy is finding entry to the
landscape of prescription medicines in oncology next to the
existing approaches of chemotherapy, small molecule targeted
therapies, radiation and surgery. The clinical development paths
of both agents have contributed to define and to demonstrate the
practical value of the new development paradigm.
4
Here we provide a perspective on the recent lessons in the
immunotherapy space and summarize the emerging framework
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provide credibility for future development (Fig.1).
The Evolving Framework for Immuno-Oncology
Oncology, the clinical discipline of cancer therapy, has been an
established medical specialty for several decades. Its hallmarks are
the science of cancer biology as described by Hanahan and
Weinberg;
18,19 a recognized clinical development paradigm (based
on observations with chemotherapy) for investigation of new
therapies in Phase 1, 2 and 3 clinical trials; defined criteria for
measuring therapeutic effects such as RECIST (Response
Evaluation Criteria In Solid Tumors) or WHO (World Health
Organization) criteria for solid tumors; understood kinetics of
therapeutic effects; established standards for publication of new
scientific data; and the availability of effective therapies paired
with a clear understanding of their use. All this is embedded in a
well-circumscribed community represented by organizations such
as the American Society of Clinical Oncology (ASCO) and the
European Society of Medical Oncology (ESMO). Together, these
hallmarks create a framework of credibility in which patient
care, scientific discovery, publication, clinical development and
regulatory review can take place.
Despite clear evidence that the whole class of cancer immuno-
therapies has critical unique features that are different from those
of the established classical therapeutic approaches in oncology, the
field did not yet create an appropriate alternative methodological
framework accommodating these class-specific characteristics.
Rather, to minimize controversy and gain recognition in
oncology, investigations of immunotherapies utilized the
existing development pathway that was based on cytotoxic
drugs. This ultimately may have contributed to many failures
in development.
Between 2004 and today, CIC and CIMT filled this void
by creating a systematic framework incorporating broad
community knowledge and providing needed tools for
successful development of immunotherapies (Table 1).
Cornerstones of a New Development Paradigm
for Cancer Immunotherapy
The process began with the proposal of a clinical develop-
ment paradigm. In 2004, much knowledge around develop-
mental problems and potential solutions existed in the field,
however, there had been little consensus on how to uniformly
utilize this knowledge and pull together a more comprehens-
ive paradigm. CIC-CRI and another partner organization,
the international Society for Biological Therapy of Cancer
(iSBTc; now the Society for Immunotherapy of Cancer)
formed a community-wide initiative known as the Cancer
Vaccine Clinical Trial Working Group (CVCTWG),
including key stakeholders from academia, the biotechnology
and pharmaceutical industry and the US FDA to construct
and recommend a paradigm for development of cancer
vaccines and related immunotherapies. The proposed
paradigm recognizes differences between chemotherapy and
immunotherapy such as: (1) the optimal biologic dose is often
not the maximum tolerated dose; (2) treatment effect is not pro-
portionally linked to toxicity; (3) conventional pharmacokinetics
may not determine dose and schedule; (4) anti-tumor response is
not the sole predictor of survival; and (5) clinical effects can be
delayed in time and can occur after tumor volume increase (often
categorized as progression). The new paradigm breaks down the
development process into proof-of-principle trials and efficacy
trials, where efficacy trials are recommended to be randomized
(Phase 2 and 3 trials). Further, it offers considerations for toxicity
screening in early trials, concepts for measurement of biologic
activity, use of immune response assays in clinical trials, dose and
schedule investigation, decision points in development, trial
design, improved clinical endpoints, and combination therapy.
Besides the systematic approach to the developmental science,
much value of this paradigm lies in the consensus between all
main constituents involved with cancer immunotherapy develop-
ment namely academicians, pharmaceutical/biotech industry and
the US FDA.
5,13
New Clinical Effects Requiring
Improved Clinical Endpoints
Conventional therapies exert their effects by directly targeting
tumor cells and typically induce measurable impact on tumor
growth soon after administration or not at all. In contrast,
therapies targeting the immune system will provoke anti-tumoral
effects indirectly by first stimulating the immune system and
second leading to a broader range of response kinetics including
Figure 1. The immuno-oncology framework provides a set of methodological
improvements for the development of cancer immunotherapies, which are
tailored to this class of therapies. Each component addresses a relevant piece
of the drug development process and was evolved out of a community
consensus approach through the immunotherapy organizations CIC and CIMT.
The framework is expected to expand with ongoing evolution of the field.
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www.landesbioscience.com OncoImmunology 335delayed effects (after increase of existing tumor lesions or
appearance of new lesions possibly induced by immune infiltrates)
or stabilization of tumor lesions.
10 The latter patterns appear to
be more common than the conventional response. They likely
reflect the interplay between the immune system and the tumor
described as immunoediting.
20 The described response kinetics
also affect downstream events such as survival.
Delayed effects and stabilization of lesions influence the
standard efficacy endpoints of anti-tumor response and overall
survival and are observed across different immunotherapies.
6,9 In
both cases, endpoints need to be adjusted to address the biology.
For the survival endpoint, Kaplan-Meier curves from randomized
immunotherapy trials may show a delayed separation after
months, which directly influences the statistical power to deter-
mine treatment effects observed over the entire length of the
curves.
21 Statistical models used in randomized trials with
conventional therapies, where separation of curves occurs early
after treatment began, typically assume a constant hazard ratio
over time (proportional hazards). Alternative statistical models
tailored to address the delayed separation of curves have to
consider that all events prior to the separation do not contribute
to the differentiation between study arms after the separation,
thus leading to loss of statistical power. Such new statistical
models need to compensate for this loss of power. They may
split the hazard ratio into an early and a late component before
and after the separation of curves.
9 Importantly, the loss of
power and absence of early effects should be carefully considered
when designing randomized trials with early interim and
futility analyses.
Modified Response Criteria for Immunotherapies
Standard WHO
22 or RECIST
23 criteria to assess clinical activity of
anti-cancer agents were defined to capture effects of cytotoxic
agents using tumor shrinkage as their measure of activity. Due
to the new biology described above, the response patterns of
immunotherapy extend beyond those of chemotherapy, and may
manifest after a period of stable disease or after initial tumor
burden increase or appearance of new lesions, which may reflect
infiltration of lymphocytes into the tumor.
10,24 Many investigators
have noted such patterns but did not systematically describe
them due to lack of suitable response criteria.
25,26 Principles for
development of new response criteria were derived from
community workshops.
5 Subsequent large data sets supporting
the development of new response criteria were generated as part of
the ipilimumab (anti-CLTLA-4) development program encom-
passing 487 advanced melanoma patients.
10 The resulting data
characterized four patterns of response. (1) immediate response;
Table 1. The framework for immuno-oncology: Solutions for common challenges
Challenge Solution Perspective Refs.
Use of chemotherapy principles
for clinical development of
immunotherapy
New clinical development paradigm for
immunotherapy with key components:
(1) development phases for proof-of-principle
and efficacy; (2) toxicity screening, (3) measurement
of biologic activity, (4) immune response
measurement in clinical trials, (5) dose and schedule,
(6) developmental decision points, (7) trial design,
(8) clinical endpoints, (9) combination therapy
A defined and reproducible path
for adequate development of
cancer immunotherapies
5
Clinical kinetics of
immunotherapies not reflected
by conventional endpoints
Adjustment of endpoints to immunotherapy
biology
More complete detection of efficacy 9
No recognized system to
measure all patterns of
immunotherapy clinical activity
Immunotherapy response criteria derived
from RECIST and WHO: Immune-related
Response Criteria (irRC)
Capture all clinical activity patterns
for a reliable assessment of activity
signals in early trials
10
High data variability for
immune monitoring in
multi-center trials
Harmonization guidelines and quality
assurance for immune monitoring assays
Enable reproducible investigation of
immune response as biomarkers in clinical
development. Subsequently, enable clinical
qualification and investigate surrogacy.
28–31
Inconsistent reporting of
immune monitoring results
in scientific publications
Reporting framework for scientific publications:
Minimal Information About T-cell Assays (MIATA)
Transparency of results and
comparability across centers and trials
11, 12
Limited integration and
distribution of key scientific
and developmental knowledge
Focused scientific exchange between
academia, industry and regulators through
meetings and workshops
Broad access of new and evolving
knowledge and processes across
the community
www.cancerresearch.
org/consortium
www.cimt.eu
Absence of regulatory
guidance for cancer
immunotherapy development
Broad scientific exchange with participation
of regulators to support guidance document
development
Credible development criteria
for prospective use
13, 14
Additional components Based on community need Evolution of framework
Table 1 adapted from reference 4, with permission.
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burden; (3) response after tumor burden increase (possible
lymphocyte infiltration); and (4) response in the presence of
new lesions. The resulting response criteria, termed immune-
related response criteria (irRC) are generally based on WHO and
RECIST criteria, describe tumor burden as a continuous variable
over time, account for new lesions in the overall tumor burden
and ask for confirmation of progression similar to the established
confirmation of response at a subsequent time point after first
detection. Available data suggest that irRC identify patients with
previously unrecognized benefit as indicated by favorable survival
outcomes of patients with novel response patterns as compared
with patients with progressive disease.
10 However, the irRC still
are undergoing prospective validation.
Managing Data Variability
in Immune Biomarker Development
As immunotherapy targets immune cells and not tumors, the
monitoring of treatment-induced immune responses defines
relevant parameters for elucidation of the therapeutic mode of
action and the description of early biologic effects prior to reaching
clinical endpoints. Consequently, immunological monitoring using
reliableandreproducibleassayscanenhance clinicaldevelopmentby
providing information on (1) determining whether an immune
intervention hit the biological target; (2) defining dose and schedule
for the intervention; (3) measuring synergistic effects for therapeutic
combinations; (4) defining study populations; (5) measuring
therapeutic effects as biological activity; or (6) predicting clinical
outcomes as surrogates for clinical benefit.
27
Commonly used cellular immune assays to determine the
function, phenotype and frequency of antigen-specific T cells and
other immune effectors (e.g., ELISPOT, intracellular cytokine
staining, and HLA-peptide multimer staining) bear high data
variability.
11 This variability has contributed to the field’sc h a l l e n g e
to develop biomarkers for the above clinical applications. A possible
strategy to reduce data variability observed across institutions can
now be proposed. Immune response assay harmonization, which
provides an external quality-control mechanism and guidance for
assay conduct was undertaken by CIC and CIMT in the context
large international proficiency panel programs.
As a result of these proficiency panels, in which more than 120
laboratories from academia, the biotechnology and the pharma-
ceutical industry from all over the world are participating, assay
harmonization has been proposed as a solution (4) to manage data
variability. Assay harmonization can increase assay performance
within laboratories and decrease variation of results generated
across institutions
28-33 thereby offering a tool to improve data
reliability for immune monitoring and enhance clinical develop-
ment of immune therapies at any stage of assay evolution.
8,34
Harmonization of assay conduct reminds of the successful
initiatives of ICH-GCP for clinical protocols.
35 The broad usage
of assay harmonization may bring immune monitoring to the
forefront of immune biomarker development, support a better
understanding of therapeutic modes of action and guide decision
making in clinical development.
36
Increasing Consistency in Reporting
of Immune Monitoring Results
Variability is not only limited to data resulting from immune
monitoring experiments. In addition, there is wide variability of
presentation of methods and results in scientific publications.
Notably, as of today, many publications of T-cell assay experi-
ments lack information on some or many of the critical variables
known to impact on assay performance thus not allowing the
reader to fully understand or reproduce the experiment. A pub-
lication framework defining a minimum set of critical information
of assay reports would provide greater transparency to the scientific
community about what experiment was done under which con-
ditions and with which results. Based on the concept of Minimum
Information About Biological and Biomedical Investigations
(MIBBI),
37 which created such a mechanism over the last decade
for more than 30 biological assays such as DNA microarrays,
RNAi experiments or cellular assays, CIC and CIMT started the
Minimal Information About T-Cell Assays (MIATA) project.
11
MIATA aims to establish a framework for publication of T cell
assay results generated in clinical trials. The MIATA proposal is
based on an extensive community-wide vetting process over
approximately 2 y incorporating the expertise and concerns of more
than 120 individuals from all areas of clinical immunology and
is aiming for broad acceptance.
12 The final version of MIATA is
currently being prepared and will become available in 2012.
Integration and Distribution
of Key Scientific Knowledge
Knowledge growth is exponential in most scientific disciplines.
However, filtration of the relevant information to facilitate
practical progress is not straightforward. To achieve this for the
cancer immunotherapy space, CIC (www.cancerresearch.org/
consortium) and CIMT (www.cimt.eu) have adopted a simple
and focused process to address challenges of the field in a one-at-a-
time approach through workshops and annual scientific meetings.
Both networks are open communities with wide participation
among key stakeholders. One guiding principle is to foster the
exchange of scientific information among colleagues active in basic
science, clinical translation, industrial development and regulatory
affairs to initiate field-spanning interactions. By bringing together
the knowledge of different stakeholders from this still fragmented
field, an integrative platform is steadily developing with synergistic
effects that can only be reached through collaboration. Another
dimension of knowledge transfer was reached by the formation of a
trans-Atlantic collaboration between both associations leading to
cross-fertilization and an avoidance of redundancy. Continued
community participation and contribution of knowledge is a
cornerstone of this process to address further challenges of the field
and expand the framework for immuno-oncology.
Regulatory Guidance
The described science and new concepts for immunotherapy
development evolved under CIC and CIMT auspices over several
www.landesbioscience.com OncoImmunology 337years and with the participation of all major stakeholders from
academia, biotechnology and pharmaceutical industries, and the
US FDA. In 2007, the FDA hosted a workshop where these
topics were reviewed. Subsequently, the FDA published a draft
regulatory guidance on “Clinical Considerations for Therapeutic
Cancer Vaccines”
13 where many of these topics were included.
The FDA draft document went through a public consultation
period and has become available in its final version in late 2011.
Recently, the European Medicines Agency (EMA) issued a
concept paper to stimulate public feedback on a proposed revision
of the guidance on “evaluation of anticancer medicinal products
in man.” Notably, the concept paper is specifically addressing
clinical endpoints for biologics and aims to include a section on
cancer vaccines.
14 As the regulatory landscape is constantly
evolving, CIMT has formally initiated a working group focusing
on regulatory research that is screening for new draft guidance
documents undergoing public consultations. The working group
collects expert opinions among the network’s members and
integrates all comments to one consolidated response representing
the expertise of the community. Similarly, the CIC Executive
Committee offers responses to regulatory guidance documents.
CIC and CIMT aim for integration of both positions. This
process enables the community to speak with a more uniform
voice and makes it easier for officials at FDA and EMA to review
and assess community positions.
Anti-CTLA-4 Antibody Development:
A Clinical Case Study
The importance of the new immunotherapy paradigm is
illustrated through the example of anti-CTLA-4 antibody
development.
4,17 Clinical investigation of anti-CTLA-4 antibodies
started at the biotechnology company Medarex in 2000 with
Phase 1 and 2 trials indicating close to 10% response rates as a
signal of clinical activity in patients with advanced melanoma.
Interest from big pharma for developing anti-CTLA-4 blocking
antibodies led to independent licensing deals with Pfizer and
Bristol-Myers Squibb (BMS) for isoforms of the antibody and two
parallel development programs in advanced melanoma with
tremelimumab (Pfizer) and ipilimumab (BMS), respectively.
Both programs initially used chemotherapy criteria to guide their
development choices.
4 As per its design, the tremelimumab
program conducted an early interim analysis with conventional
futility criteria for survival in its Phase 3 study and could not
observe a survival improvement. Consequently, the Phase 3 study
was terminated for futility as per Data Monitoring Committee
recommendations.
38 Two years later, extended follow-up on the
study population revealed a separation of survival curves.
39
Through the interaction of the ipilimumab program with the
CIC efforts to create a new immunotherapy paradigm, the
scientific approach for ipilimumab evolved and led to the change
of the primary endpoint for both of its Phase 3 studies in
advanced melanoma to overall survival with no early interim
analyses, which could mislead the survival assessment.
4,9,16,17 The
final analysis of survival of two Phase 3 studies demonstrated
improved survival (HR 0.66 and HR 0.72, respectively) and
supported the approval for patients with pretreated metastatic
melanoma. Based on the understanding of immunotherapy
development BMS acquired Medarex in 2009 in a transaction
valued $2.4 billion and is now developing a pipeline of immuno-
oncology agents resulting from the acquisition.
40
The development paths for ipilimumab and tremelimumab and
their respective results illustrate the importance of the science-
driven clinical development paradigm for immunotherapies and
of collaboration across various constituents to direct scientific
progress. These observations also suggest that the prospective
application of the new paradigm may help avoid critical pitfalls for
future immunotherapy programs.
Conclusions
Our scientific knowledge of tumor immunology has steadily
evolved,
41 and many cancer immunotherapy technologies have
entered clinical trials.
3,6,42 An obvious weak spot for development
has been the absence of a tailored clinical development paradigm
for immunotherapies that distinguishes it from the widely used
chemotherapy paradigm.
Over the past decade we have started to systematically
address the unique characteristics of immunotherapeutic agents
in clinical trials and developed a methodological framework to
enable reproducible development.
4 This ranges from a defined
immunotherapy development paradigm, improved clinical end-
points, harmonization concepts for immune monitoring to
support immunological biomarker development, and minimal
information for publication to enhance interpretability and
reproducibility, as well as regulatory guidance. This new
framework may provide for reproducible and likely more
successful development of cancer immunotherapies and lays
the foundation for the new clinical sub-specialty of immuno-
oncology (Fig.1). The framework may evolve with the
growing field.
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